Status:

COMPLETED

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.

Collaborating Sponsors:

Teva Neuroscience, Inc.

H. Lundbeck A/S

Conditions:

Parkinson's Disease

Eligibility:

All Genders

Brief Summary

Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have sto...

Eligibility Criteria

Inclusion

  • Subjects who participated in the ADAGIO study, and who entered the active phase of the study and
  • Subjects who are currently on rasagiline treatment (or subjects who have stopped rasagiline treatment, are willing to restart treatment, and in the opinion of the investigator will gain clinical benefit from restarting treatment) and
  • Subjects with a diagnosis of Parkinson's disease and
  • Subjects willing and able to give written informed consent

Exclusion

  • Subjects who have discontinued rasagiline treatment due to an adverse event and have not restarted rasagiline treatment subsequently.
  • Subjects who cannot be given rasagiline due to any exclusion based on the local label (including pregnancy or nursing women) or due to the use of medications contraindicated for concomitant use with rasagiline according to local label
  • Subjects with a medical condition that is considered by the investigator as significant enough to prevent participation

Key Trial Info

Start Date :

July 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

684 Patients enrolled

Trial Details

Trial ID

NCT00936676

Start Date

July 1 2009

End Date

March 1 2013

Last Update

April 11 2016

Active Locations (102)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 26 (102 locations)

1

Teva Investigational Site 7054

Birmingham, Alabama, United States

2

Teva Investigational Site 7006

Tucson, Arizona, United States

3

Teva Investigational Site 7018

Irvine, California, United States

4

Teva Investigational Site 7019

La Jolla, California, United States